VanEck Pharmaceutical ETF
PPH
49 hedge funds and large institutions have $131M invested in VanEck Pharmaceutical ETF in 2018 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 7 closing their positions.
27% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 11
16% more capital invested
Capital invested by funds: $113M → $131M (+$17.9M)
1% more ownership
Funds ownership: 46.22% → 47.22% (+1%)
6% less funds holding
Funds holding: 52 → 49 (-3)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $920K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$9.18M |
| 2 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
+$8.81M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.74M |
| 4 |
VF
Virtu Financial
New York
|
+$1.43M |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$514K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$4.44M |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$1.45M |
| 3 |
Citigroup
New York
|
-$1.01M |
| 4 |
CCT
Country Club Trust
Kansas City,
Missouri
|
-$890K |
| 5 |
MA
Mutual Advisors
Omaha,
Nebraska
|
-$823K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MA
51
Mutual Advisors
Omaha,
Nebraska
| – | -$823K | -14,485 | Closed |
|
|
RJFSA
52
Raymond James Financial Services Advisors
St. Petersburg,
Florida
| – | -$240K | -4,220 | Closed |
|
|
KFC
53
Klingenstein Fields & Co
New York
| – | -$216K | -3,800 | Closed |
|
|
APP
54
Avantax Planning Partners
Dubuque,
Iowa
| – | -$63K | -1,113 | Closed |
|
55
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | -$23K | -400 | Closed |
|
PPH Hedge Fund Activity: Q2 2018 in Review
49 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q2 2018, worth a combined $131M — up 16% from $113M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of PPH and 4 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 14 added.
The largest buyer was Goldman Sachs, adding an estimated $9.18M. The largest seller was Bank of America, cutting an estimated $4.44M.
- 49 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q2 2018, down from 52 in Q1 2018.
- Funds reported $131M of VanEck Pharmaceutical ETF stock for Q2 2018, up 16% quarter-over-quarter.
- 4 funds opened new VanEck Pharmaceutical ETF positions in Q2 2018 and 7 closed out, a net change of -3 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q2 2018 was Goldman Sachs, an estimated $9.18M added.
- The largest VanEck Pharmaceutical ETF seller in Q2 2018 was Bank of America, an estimated $4.44M sold.
Based on aggregated 13F filings for Q2 2018.